George B. Naff
Case Western Reserve University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by George B. Naff.
Journal of Trauma-injury Infection and Critical Care | 1989
William J. Schirmer; James M. Schirmer; George B. Naff; Donald E. Fry
This study examines the influence of complement on systemic hemodynamics following severe thermal injury in rats. Animals were injected intraperitoneally at t = -36 and t = -24 hours with either cobra venom factor (20 units/kg/dose; n = 56) to delete circulating complement or with saline alone (n = 64). Rats within each subset were then subjected to either a 50% TBSA full-thickness scald burn or sham burn. Cardiac output (CO), mean arterial pressure (MAP), heart rate, systemic vascular resistance (SVR), stroke volume, and cardiac power as well as hematocrit and the change in per cent complement activity were determined at various time periods between 15 minutes and 25 hours after the burn. In normocomplementemic animals the burn produced a marked early (t = 3-6 hours) depression in CO and MAP with a rise in SVR. Over time the hemodynamics returned to normal (t = 12 hours) and eventually approached a hyperdynamic response (t = 24 hours). Serum hemolytic complement activity fell immediately and progressively after the burn, indicating significant complement activation. Complement depletion attenuated the early decline in CO and sharply lowered the rise in SVR in the early postburn period. In addition, complement depletion improved heart rate and stroke volume and appeared to preserve/enhance late (t = 24 hours) cardiac function. This study suggests that complement activation contributes to the depression in cardiac output in the early postburn period.
Journal of Trauma-injury Infection and Critical Care | 1987
William J. Schirmer; James M. Schirmer; George B. Naff; Donald E. Fry
This study examines the effects of complement activation and of complement-induced oxygen radical production on the principal determinant of hepatic function, i.e., effective hepatic blood flow (EHBF). Female Sprague-Dawley rats received cobra venom factor, 40 units/kg, in two divided doses at 30-minute intervals. At t = 2 hours, thermodilution cardiac output, mean arterial pressure, heart rate, hematocrit, and EHBF by galactose clearance were determined. Complement activation produced a significant depression in EHBF independent of changes in systemic perfusion. To determine whether oxygen radicals participated in the insult, additional animals were pretreated with superoxide dismutase, 6 mg/kg, plus catalase, 15 mg/kg, immediately before complement activation. Concomitant treatment with the oxygen radical scavengers attenuated the degree of complement-induced hepatic ischemia, again independent of effects on systemic perfusion. This study suggests that the reduction in hepatic blood flow that accompanies animal models of trauma and sepsis may result, in part, from the sequelae of complement activation with oxygen radicals as secondary mediators.
Journal of Surgical Research | 1977
F. Thomas; George B. Naff; J. Thomas; K. Dvorak
Clinical hyperacute kidney rejection (HKR) was first described by KissmyerNeilsen et al. in 1966 [I 11. Starzl et al. described a high rate of HKR in transplants done across major ABO incompatibilities [ 181. Williams and co-workers demonstrated the relationship of this phenomenon to humoral antibodies directed against donor kidney antigens [26], and Terasaki and Singal showed the relationship of HKR to a positive donor-recipient cross match [ 191. With the development of more sensitive cross-matching techniques, the incidence of HKR has declined markedly [19] although HKR still continues to occur in l12% of renal transplants. This rejection phenomenon is vexing because of a rather high rate of occurrence in presensitized patients and in patients requiring secondary transplantation [23]. In addition, there is currently no effective treatment for HKR. At least one group has attempted unsuccessfully to prevent HKR in sensitized patients using infusions of F(ab’), antibodies and citrate pretreatment [7]. HKR is known to involve a complementfixing antibody [ 1 l] whereas recent work has suggested that some antibodies which do not fix complement may produce a state of enhancement favoring allograft prolongation [27]. This work suggests conceptually that HKR might be abrogated and a system
Journal of Surgical Research | 1988
William J. Schirmer; James M. Schirmer; George B. Naff; Donald E. Fry
Intravascular complement activation with either zymosan or cobra venom factor (CVF) impairs hepatic blood flow. Oxygen radical scavengers given at the time of complement activation attenuate the resulting hepatic ischemia. It is not clear whether complement-stimulated phagocytes or transiently ischemic then reperfused endothelial and parenchymal cells generated the toxic oxygen radicals. In this study, a group of rats were given allopurinol (50 mg/kg/day postoperatively X 3 days plus 100 mg/kg iv at t = 0), a specific inhibitor of xanthine oxidase, prior to complement activation with CVF (20 units/kg iv at t = 30 and 60 min) to determine whether xanthine oxidase-derived oxygen radicals contributed significantly to the hepatic perfusion abnormalities. Additional rats received lodoxamide tromethamine (10 mg/kg iv bolus at t = 0 followed by 20 mg/kg/hr iv infusion), a novel and potent inhibitor of mast cell release and inhibitor of xanthine oxidase, prior to the same CVF challenge to determine whether mast cell mediators were involved in the flow disturbance. Thermodilution cardiac output, mean arterial pressure, heart rate, hematocrit, and effective hepatic blood flow (EHBF) by galactose clearance were determined at t = 2 hr. The percentage change in total hemolytic complement activity (% delta CH50) was determined between serum obtained prior to sacrifice and at t = 0. Systemic hemodynamics and HCT were for the most part unaffected regardless of pretreatment group or challenge with CVF or saline. CVF challenge produced a 25% reduction (P less than 0.05) in EHBF in vehicle-pretreated rats compared to saline challenge. Neither allopurinol nor lodoxamide tromethamine significantly improved EHBF when given prior to CVF challenge.(ABSTRACT TRUNCATED AT 250 WORDS)
Journal of Experimental Medicine | 1963
Irwin H. Lepow; George B. Naff; Earl W. Todd; Jack Pensky; C. F. Hinz
Journal of Experimental Medicine | 1969
Oscar D. Ratnoff; Jack Pensky; Derek Ogston; George B. Naff
Journal of Experimental Medicine | 1967
Oscar D. Ratnoff; George B. Naff
Journal of Experimental Medicine | 1964
George B. Naff; Jack Pensky; Irwin H. Lepow
Journal of Experimental Medicine | 1968
George B. Naff; Oscar D. Ratnoff
Journal of Laboratory and Clinical Medicine | 1973
George B. Naff; Peter H. Byers